Sanofi-Aventis S.A. ADR (SNY)

$47.20 -0.40 (-0.84%)
Market Cap 116.10B
Revenue (ttm) 47.92B
Net Income (ttm) 6.02B
EPS (ttm) N/A
PE Ratio 11.56
Forward PE 10.05
Profit Margin 12.55%
Debt to Equity Ratio 0.27
Volume 4,257,500
Avg Vol 2,577,636
Day's Range N/A - N/A
Shares Out 2.44B
Stochastic %K 20%
Beta 0.45
Analysts Strong Sell
Price Target $59.01

Company Profile

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 33 1 53 77 40 00
Address:
46, avenue de la Grande Armée, Paris, France
MoneyGroupLLC
MoneyGroupLLC Jan. 14 at 5:29 AM
Enter: $SNY Calls Strike Price: $48 Expiry Date: FEB 20 2026 Buy in Price: $1.50 - $1.85 Sell Price: $2.56 Profit : +71% (Turn every $1 into $1.71) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
MQuick
MQuick Jan. 13 at 5:56 PM
$GANX we are waiting $SNY
0 · Reply
ZacksResearch
ZacksResearch Jan. 13 at 2:39 PM
🚨 $SNY just changed the game in Type 1 diabetes. Sanofi’s Teizeild just won EU approval as the first disease-modifying drug shown to delay stage 3 type 1 diabetes in adults and children aged eight and older — a major milestone, not just another incremental approval. 🧬 Big implications here. Full details on why this matters 👉 https://www.zacks.com/stock/news/2816386/sanofis-teizeild-gets-eu-approval-for-treating-type-1-diabetes?cid=sm-stocktwits-2-2816386-teaser-28577&ADID=SYND_STOCKTWITS_TWEET_2_2816386_TEASER_28577
0 · Reply
ZacksResearch
ZacksResearch Jan. 13 at 1:39 PM
$SNY gets key EU approval for Teplizumab — but what does this mean for investors? 💡 The European Commission has greenlit Teplizumab to delay stage 3 T1D in patients 8 years and older, marking it as the first disease-modifying drug of its kind in the EU. Despite this milestone, SNY shares have slipped 1.7% over the past year, trailing the industry's 21.9% rise. Discover the impact on SNY’s portfolio here 👉 https://www.zacks.com/stock/news/2816386/sanofis-teizeild-gets-eu-approval-for-treating-type-1-diabetes?cid=sm-stocktwits-2-2816386-body-28575&ADID=SYND_STOCKTWITS_TWEET_2_2816386_BODY_28575
0 · Reply
MQuick
MQuick Jan. 13 at 12:31 PM
$GANX tick tock $SNY
0 · Reply
MQuick
MQuick Jan. 12 at 11:22 PM
$GANX its time $SNY
0 · Reply
Quantumup
Quantumup Jan. 12 at 9:19 PM
Raymond James reiterated $COGT Strong Buy-$60, and provided its WW product revenue ests for bezuclasinib in 3 indications for FY27-30, w/ 1 NDA submitted & 2 on deck in 1H26, ahead of competitors conference this week. $SNY - BPMC $NVS $OPHLY GSK $CLDX Raymond James said in its note, Recall, Cogent submitted an NDA for NonAdvSM in December based on positive SUMMIT data presented earlier last year and expects FDA to accept the NDA by the end of February 2026. Moreover, Cogent is on track to submit two more NDAs for GIST and AdvSM in April 2026 and 1H26, respectively. Overall, by Cogent's estimates and our model, bezuclastinib's commercialization is on deck in 2H26 in all three indications, and we model total WW product revenues of $393.4M, $773.6M, $1.35B, and $1.83B for FY27- 30, respectively.
0 · Reply
BioRich
BioRich Jan. 12 at 9:10 PM
$ALT Like to share friendly reminders for $ALT Nation every now and again. They sweet to consistently live in a liberal victimhood mindset so sharing truthful reminders is always good. Sent this back in November when there was much discussion about $ALT 48W data and EoP2 meeting. Many were still pumping Biopsies at 48W (yes, the $ALT Pervi's are indeed this dumb). I/we gently reminded y'all that you're in the wrong game. Since then, $ALT is down significantly, $IVA is up significantly (even after it's SP correction for EU trading...don't ask $ALT, you won't understand, it involves numbers and math). Anyway, cheers to $IVA for continued growth. Early cheers to $SNY for your soon to be released acquisition(s). $ALT, you can't get respect if you never do anything to earn it. (Fibrosis Improvement comparison listed in original post below).
0 · Reply
Zerk4
Zerk4 Jan. 12 at 6:50 PM
$SNY Slow mover but dependable, if it holds trend while growth chops it’s quiet accumulation by real money
0 · Reply
MQuick
MQuick Jan. 12 at 5:49 PM
$GANX $RHHBY and $SNY its time
0 · Reply
Latest News on SNY
Sanofi (SAN:CA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 5:26 PM EST - 1 day ago

Sanofi (SAN:CA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

SAN

Recludix Pharma Announces Dosing of First Subjects in a Phase 1 Study of REX-8756, a Potent and Selective Oral STAT6 Inhibitor, and Achieves Associated $20 Million Milestone Payment Under Collaboration with Sanofi

Jan 12, 2026, 8:00 AM EST - 1 day ago

Recludix Pharma Announces Dosing of First Subjects in a Phase 1 Study of REX-8756, a Potent and Selective Oral STAT6 Inhibitor, and Achieves Associated $20 Million Milestone Payment Under Collaboration with Sanofi

Press Release: Sanofi's Teizeild approved in the EU for patients with stage 2 type 1 diabetes

Jan 12, 2026, 1:00 AM EST - 1 day ago

Press Release: Sanofi's Teizeild approved in the EU for patients with stage 2 type 1 diabetes

BrightInsight's Patient App, developed with Sanofi, shows positive impact in patient treatment adherence and persistence

Jan 7, 2026, 8:30 AM EST - 6 days ago

BrightInsight's Patient App, developed with Sanofi, shows positive impact in patient treatment adherence and persistence

Enable Injections Announces $30 Million Investment from Sanofi to Accelerate Manufacturing Capabilities

Jan 6, 2026, 7:30 AM EST - 7 days ago

Enable Injections Announces $30 Million Investment from Sanofi to Accelerate Manufacturing Capabilities

Sanofi Says FDA Agrees to Review Diabetes Drug Age Range

Jan 5, 2026, 1:40 AM EST - 8 days ago

Sanofi Says FDA Agrees to Review Diabetes Drug Age Range

Press Release: Sanofi's Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes

Jan 5, 2026, 1:00 AM EST - 8 days ago

Press Release: Sanofi's Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes

Exclusive: Drugmakers raise US prices on 350 medicines despite pressure from Trump

Dec 31, 2025, 6:08 AM EST - 13 days ago

Exclusive: Drugmakers raise US prices on 350 medicines despite pressure from Trump

GSK LLY NVS PFE

This Biotech Stock Is Soaring. Sanofi Is Buying It for $2.2 Billion.

Dec 24, 2025, 7:59 AM EST - 20 days ago

This Biotech Stock Is Soaring. Sanofi Is Buying It for $2.2 Billion.

DVAX

Sanofi to acquire US biotech Dynavax for $2.2 billion

Dec 24, 2025, 3:08 AM EST - 20 days ago

Sanofi to acquire US biotech Dynavax for $2.2 billion

DVAX

Sanofi to Buy Vaccine Maker Dynavax in $2.2 Billion Deal

Dec 24, 2025, 1:49 AM EST - 20 days ago

Sanofi to Buy Vaccine Maker Dynavax in $2.2 Billion Deal

DVAX

Press Release: Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline

Dec 24, 2025, 1:15 AM EST - 20 days ago

Press Release: Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline

DVAX

Press Release: Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis

Dec 24, 2025, 1:00 AM EST - 20 days ago

Press Release: Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis

Press Release: Sanofi's Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia

Dec 23, 2025, 9:06 AM EST - 21 days ago

Press Release: Sanofi's Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia

Press Release: Sanofi and Regeneron's Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma

Dec 23, 2025, 1:00 AM EST - 21 days ago

Press Release: Sanofi and Regeneron's Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma

REGN

Sanofi: Information concerning the total number of voting rights and shares - November 2025

Dec 22, 2025, 12:35 PM EST - 22 days ago

Sanofi: Information concerning the total number of voting rights and shares - November 2025

Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients pay

Dec 19, 2025, 4:09 PM EST - 25 days ago

Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients pay

BMY GSK MRK AMGN GILD NVS

Trump strikes deal with US drugmakers to cut Medicaid medicine costs

Dec 19, 2025, 3:14 PM EST - 25 days ago

Trump strikes deal with US drugmakers to cut Medicaid medicine costs

AMGN BMY GILD GSK MRK NVS

Nine of the largest pharma companies ink deals with Trump to lower drug prices

Dec 19, 2025, 2:34 PM EST - 25 days ago

Nine of the largest pharma companies ink deals with Trump to lower drug prices

AMGN BMY GILD GSK MRK NVS

Press Release: Sanofi reaches agreement with the US government to lower medicine costs while strengthening innovation

Dec 19, 2025, 2:21 PM EST - 25 days ago

Press Release: Sanofi reaches agreement with the US government to lower medicine costs while strengthening innovation

Sanofi (SAN:CA) Discusses Year-End Late-Stage Pipeline Review With Focus on Clinical and Regulatory Developments Transcript

Dec 16, 2025, 9:59 PM EST - 4 weeks ago

Sanofi (SAN:CA) Discusses Year-End Late-Stage Pipeline Review With Focus on Clinical and Regulatory Developments Transcript

South Korea's ADEL signs up to $1.04 billion Alzheimer's drug development deal with Sanofi

Dec 15, 2025, 6:57 PM EST - 4 weeks ago

South Korea's ADEL signs up to $1.04 billion Alzheimer's drug development deal with Sanofi

Sanofi: Today's Tolebrutinib Setback Shouldn't Worry Shareholders - This Is Why

Dec 15, 2025, 2:51 PM EST - 4 weeks ago

Sanofi: Today's Tolebrutinib Setback Shouldn't Worry Shareholders - This Is Why

Sanofi Expands Dren Bio Partnership With Potential $1.7 Billion Autoimmune Disease Collaboration

Dec 15, 2025, 1:10 PM EST - 4 weeks ago

Sanofi Expands Dren Bio Partnership With Potential $1.7 Billion Autoimmune Disease Collaboration

Dren Bio to collaborate with Sanofi to develop autoimmune disease therapies for up to $1.7 billion

Dec 15, 2025, 8:21 AM EST - 4 weeks ago

Dren Bio to collaborate with Sanofi to develop autoimmune disease therapies for up to $1.7 billion

Dren Bio Expands Strategic Collaboration with Sanofi to Develop Next-Generation B-Cell Depletion Therapy

Dec 15, 2025, 8:05 AM EST - 4 weeks ago

Dren Bio Expands Strategic Collaboration with Sanofi to Develop Next-Generation B-Cell Depletion Therapy

Sanofi shares slide as FDA delays MS drug decision and late-stage trial disappoints

Dec 15, 2025, 5:48 AM EST - 4 weeks ago

Sanofi shares slide as FDA delays MS drug decision and late-stage trial disappoints

Sanofi stock slumps after two setbacks on multiple-sclerosis drug

Dec 15, 2025, 4:43 AM EST - 4 weeks ago

Sanofi stock slumps after two setbacks on multiple-sclerosis drug

Sanofi flags delay in FDA's decision on tolebrutinib, shares fall

Dec 15, 2025, 3:49 AM EST - 4 weeks ago

Sanofi flags delay in FDA's decision on tolebrutinib, shares fall

Sanofi Multiple Sclerosis Drug Hit by Double Setback

Dec 15, 2025, 1:56 AM EST - 4 weeks ago

Sanofi Multiple Sclerosis Drug Hit by Double Setback

Press Release: Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis

Dec 15, 2025, 1:05 AM EST - 4 weeks ago

Press Release: Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis

Press Release : Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis

Dec 15, 2025, 1:00 AM EST - 4 weeks ago

Press Release : Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis

Sanofi Scores Two Major China Approvals For Rare Blood Disorder Drugs

Dec 11, 2025, 1:11 PM EST - 4 weeks ago

Sanofi Scores Two Major China Approvals For Rare Blood Disorder Drugs

Sanofi's Bleeding-Disorder Treatments Get Approval in China

Dec 11, 2025, 1:42 AM EST - 4 weeks ago

Sanofi's Bleeding-Disorder Treatments Get Approval in China

Press Release: Sanofi's Qfitlia and Cablivi approved in China, expanding care for rare diseases

Dec 11, 2025, 1:00 AM EST - 4 weeks ago

Press Release: Sanofi's Qfitlia and Cablivi approved in China, expanding care for rare diseases

InduPro Therapeutics Announces Strategic Investment from Sanofi and a Research Collaboration to Advance a Novel Bispecific for Autoimmune Disorders

Dec 10, 2025, 8:00 AM EST - 4 weeks ago

InduPro Therapeutics Announces Strategic Investment from Sanofi and a Research Collaboration to Advance a Novel Bispecific for Autoimmune Disorders

Vaccine makers raise concerns over US panel's shift away from hepatitis B shots for newborns

Dec 5, 2025, 1:35 PM EST - 5 weeks ago

Vaccine makers raise concerns over US panel's shift away from hepatitis B shots for newborns

GSK MRK

Press Release: Sanofi completes acquisition of Vicebio

Dec 4, 2025, 5:00 AM EST - 5 weeks ago

Press Release: Sanofi completes acquisition of Vicebio

LabGenius Therapeutics Announces New Collaboration with Sanofi for Multiple AI/ML-driven Antibody Optimisation Programmes

Dec 4, 2025, 3:00 AM EST - 5 weeks ago

LabGenius Therapeutics Announces New Collaboration with Sanofi for Multiple AI/ML-driven Antibody Optimisation Programmes

Sanofi (SAN:CA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec 3, 2025, 7:23 PM EST - 5 weeks ago

Sanofi (SAN:CA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

SAN

Sanofi (SAN:CA) Presents at Evercore 8th Annual Healthcare Conference Transcript

Dec 3, 2025, 7:03 AM EST - 5 weeks ago

Sanofi (SAN:CA) Presents at Evercore 8th Annual Healthcare Conference Transcript

SAN

Sanofi Faces Surprise HQ Search As French Authorities Expand Tax Probe

Nov 25, 2025, 1:30 PM EST - 7 weeks ago

Sanofi Faces Surprise HQ Search As French Authorities Expand Tax Probe

Press Release: Sanofi and Regeneron's Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria

Nov 25, 2025, 1:00 AM EST - 7 weeks ago

Press Release: Sanofi and Regeneron's Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria

REGN

Bristol Myers, Sanofi sued by Texas over Plavix

Nov 20, 2025, 4:06 PM EST - 7 weeks ago

Bristol Myers, Sanofi sued by Texas over Plavix

BMY

Lifordi Immunotherapeutics Secures Strategic Investment from Sanofi Ventures and Additional Capital from Existing Investors

Nov 18, 2025, 12:20 PM EST - 2 months ago

Lifordi Immunotherapeutics Secures Strategic Investment from Sanofi Ventures and Additional Capital from Existing Investors

Global drugmakers rush to boost US presence as tariff threat looms

Nov 18, 2025, 8:25 AM EST - 2 months ago

Global drugmakers rush to boost US presence as tariff threat looms

ABBV AMGN AZN BIIB GILD GSK JNJ

Sanofi's type 1 diabetes drug recommended for EU approval

Nov 14, 2025, 8:21 AM EST - 2 months ago

Sanofi's type 1 diabetes drug recommended for EU approval

Press Release: Sanofi's Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetes

Nov 14, 2025, 6:30 AM EST - 2 months ago

Press Release: Sanofi's Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetes

Press Release: ACAAI: Sanofi and Regeneron's Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review

Nov 7, 2025, 8:00 AM EST - 2 months ago

Press Release: ACAAI: Sanofi and Regeneron's Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review

REGN

MoneyGroupLLC
MoneyGroupLLC Jan. 14 at 5:29 AM
Enter: $SNY Calls Strike Price: $48 Expiry Date: FEB 20 2026 Buy in Price: $1.50 - $1.85 Sell Price: $2.56 Profit : +71% (Turn every $1 into $1.71) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
MQuick
MQuick Jan. 13 at 5:56 PM
$GANX we are waiting $SNY
0 · Reply
ZacksResearch
ZacksResearch Jan. 13 at 2:39 PM
🚨 $SNY just changed the game in Type 1 diabetes. Sanofi’s Teizeild just won EU approval as the first disease-modifying drug shown to delay stage 3 type 1 diabetes in adults and children aged eight and older — a major milestone, not just another incremental approval. 🧬 Big implications here. Full details on why this matters 👉 https://www.zacks.com/stock/news/2816386/sanofis-teizeild-gets-eu-approval-for-treating-type-1-diabetes?cid=sm-stocktwits-2-2816386-teaser-28577&ADID=SYND_STOCKTWITS_TWEET_2_2816386_TEASER_28577
0 · Reply
ZacksResearch
ZacksResearch Jan. 13 at 1:39 PM
$SNY gets key EU approval for Teplizumab — but what does this mean for investors? 💡 The European Commission has greenlit Teplizumab to delay stage 3 T1D in patients 8 years and older, marking it as the first disease-modifying drug of its kind in the EU. Despite this milestone, SNY shares have slipped 1.7% over the past year, trailing the industry's 21.9% rise. Discover the impact on SNY’s portfolio here 👉 https://www.zacks.com/stock/news/2816386/sanofis-teizeild-gets-eu-approval-for-treating-type-1-diabetes?cid=sm-stocktwits-2-2816386-body-28575&ADID=SYND_STOCKTWITS_TWEET_2_2816386_BODY_28575
0 · Reply
MQuick
MQuick Jan. 13 at 12:31 PM
$GANX tick tock $SNY
0 · Reply
MQuick
MQuick Jan. 12 at 11:22 PM
$GANX its time $SNY
0 · Reply
Quantumup
Quantumup Jan. 12 at 9:19 PM
Raymond James reiterated $COGT Strong Buy-$60, and provided its WW product revenue ests for bezuclasinib in 3 indications for FY27-30, w/ 1 NDA submitted & 2 on deck in 1H26, ahead of competitors conference this week. $SNY - BPMC $NVS $OPHLY GSK $CLDX Raymond James said in its note, Recall, Cogent submitted an NDA for NonAdvSM in December based on positive SUMMIT data presented earlier last year and expects FDA to accept the NDA by the end of February 2026. Moreover, Cogent is on track to submit two more NDAs for GIST and AdvSM in April 2026 and 1H26, respectively. Overall, by Cogent's estimates and our model, bezuclastinib's commercialization is on deck in 2H26 in all three indications, and we model total WW product revenues of $393.4M, $773.6M, $1.35B, and $1.83B for FY27- 30, respectively.
0 · Reply
BioRich
BioRich Jan. 12 at 9:10 PM
$ALT Like to share friendly reminders for $ALT Nation every now and again. They sweet to consistently live in a liberal victimhood mindset so sharing truthful reminders is always good. Sent this back in November when there was much discussion about $ALT 48W data and EoP2 meeting. Many were still pumping Biopsies at 48W (yes, the $ALT Pervi's are indeed this dumb). I/we gently reminded y'all that you're in the wrong game. Since then, $ALT is down significantly, $IVA is up significantly (even after it's SP correction for EU trading...don't ask $ALT, you won't understand, it involves numbers and math). Anyway, cheers to $IVA for continued growth. Early cheers to $SNY for your soon to be released acquisition(s). $ALT, you can't get respect if you never do anything to earn it. (Fibrosis Improvement comparison listed in original post below).
0 · Reply
Zerk4
Zerk4 Jan. 12 at 6:50 PM
$SNY Slow mover but dependable, if it holds trend while growth chops it’s quiet accumulation by real money
0 · Reply
MQuick
MQuick Jan. 12 at 5:49 PM
$GANX $RHHBY and $SNY its time
0 · Reply
JTebow_CWS
JTebow_CWS Jan. 12 at 12:30 PM
$SABS $VRNA $SNY Excellent short explanation. Glad to own shares here. https://youtube.com/shorts/P2cpE8f20HE?si=EC-MPczGItwvTfUP
0 · Reply
JTebow_CWS
JTebow_CWS Jan. 12 at 12:27 PM
$SABS $SNY $REGN https://youtube.com/shorts/D7GKQ7dsJ_c?si=BR-glODrSaMve24c
0 · Reply
Elevate1
Elevate1 Jan. 12 at 11:24 AM
$SNY
0 · Reply
Elevate1
Elevate1 Jan. 12 at 11:23 AM
$SNY
0 · Reply
MQuick
MQuick Jan. 11 at 10:12 PM
$GANX $SNY $RHHBY you better make a move
0 · Reply
Outcomes
Outcomes Jan. 11 at 3:47 PM
$MNKD $NVO $SNY $LLY
1 · Reply
clan
clan Jan. 11 at 2:37 AM
$MNKD ADA Standards (Section 9: Pharmacologic Treatment; Figure 9.2) now recommend clinicians evaluate inhaled insulin [Afrezza] as a prandial option at every patient visit—moving it into routine care conversations and creating a catalyst for broader adoption. $NVO $SNY $LLY
3 · Reply
MoneyGroupLLC
MoneyGroupLLC Jan. 10 at 10:45 PM
Enter: $SNY Calls Strike Price: $50 Expiry Date: FEB 20 2026 Buy in Price: $1.70 - $1.80 Sell Price: $3.45 Profit : +103% (Turn every $1 into $2.03) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
JTebow_CWS
JTebow_CWS Jan. 10 at 7:24 PM
$SABS $SNY Newly acquired shares by our board members.
1 · Reply
JTebow_CWS
JTebow_CWS Jan. 10 at 7:23 PM
$SABS $SNY Powerhouse additions. These guys are not coming for failure.
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 9 at 9:35 AM
$SNY Share Price: $48.10 Contract Selected: Jun 18, 2026 $50 Calls Buy Zone: $1.72 – $2.13 Target Zone: $3.16 – $3.86 Potential Upside: 73% ROI Time to Expiration: 159 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
MQuick
MQuick Jan. 9 at 3:00 AM
$GANX lets go $RHHBY or $SNY make the first move
1 · Reply